A peroxisome proliferator-activated receptor α/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia

Molecular Endocrinology

Volumn 19, Issue 6, 2005, Pages 1593-1605

  Reifel Miller, Anne ^a   Otto, Keith ^a   Hawkins, Eric ^a   Barr, Robert ^a   Bensch, William R ^a   Bull, Chris ^a   Dana, Sharon ^a   Klausing, Kay ^b   Martin, Jose Alfredo ^a   Rafaeloff Phail, Ronit ^a   Rafizadeh Montrose, Chahrzad ^a   Rhodes, Gary ^a   Robey, Roger ^a   Rojo, Isabel ^a   Rungta, Deepa ^b   Snyder, David ^b   Wilbur, Kelly ^a   Zhang, Tony ^a   Zink, Richard ^a   Warshawsky, Alan ^a   Brozinick, Joseph T ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN LIPASE; LSN 862; MALATE DEHYDROGENASE (DECARBOXYLATING); MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PYRUVATE DEHYDROGENASE; ROSIGLITAZONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DYSLIPIDEMIA; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN SENSITIVITY; LIVER METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT STRAIN; STATISTICS; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ALKYNES; ANIMALS; BINDING, COMPETITIVE; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; CINNAMATES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HOMOZYGOTE; HUMANS; HYPERLIPIDEMIAS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, TRANSGENIC; MODELS, CHEMICAL; PPAR ALPHA; PPAR GAMMA; PROCETOFEN; PROTEIN BINDING; PROTEIN ISOFORMS; RATS; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSFECTION; TRIGLYCERIDES; TWO-HYBRID SYSTEM TECHNIQUES;

MUS MUSCULUS; RODENTIA;

EID: 22344446185     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2005-0015     Document Type: Article

References (57)

1. Taskinen MR 2001 Diabetic dyslipidemia. Atheroscler Suppl 3:47-51
2. Garber AJ, Karlsson FO 2001 Treatment of dyslipidemia in diabetes. Endocrinol Metab Clin North Am 30: 999-1010
3. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL 2000 Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:1605-1611
4. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC 1998 Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093
5. Jones IR, Swai A, Taylor R, Miller M, Laker MR, Algerti KG 1990 Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 13:855-863
6. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S 1988 Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 11:495-499
7. Issemann I, Green S 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650
8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ(PPARγ). J Biol Chem 270: 12953-12956
9. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy M-F, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud J-P, Auwerx J 2001 A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-747
10. Berger JP, Petro AE, Macnaul KL 2003 Distinct properties and advantages of a novel PPARγ selective modulator. Mol Endocrinol 17:662-676
11. Shimaya A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, Shikama H 2000 The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism 49:411-417
12. Chakrabarti R, Vikramadithyan R, Misra P, Suresh J, Rajagopalan R 2003 Balaglitazone, a quinazalone analogue of thiazolidinedione shows excellent antidiabetic and hypolipidemic potential with less adipogenic activity. Diabetes 52(Suppl 1):601P (Abstract)
13. Kawai T, Takei I, Oguma Y 1999 Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102-1107
14. Wulff E, Pedersen K, Sauerberg P 2003 Balaglitazone a new partial PPARγ agonist has a better cardiovascular safety profile and glycemic control compared with the full PPARγ agonist rosiglitazone. Diabetes 52(Suppl 1):594P (Abstract)
15. Guerre-Millo M, Gervois P, Raspe E 2000 Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642
16. Nagai Y, Nishio Y, Nakamura T, Maegawa H, Kikkawa R, Kashiwagi A 2002 Amelioration of high fructose-induced metabolic derangements by activation of PPARα. Am J Physiol Endocrinol Metab 282:E1180-E1190
17. Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott, RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC 2001 Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 42:1543-1551
18. Ye J-M, Doyal PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW 2001 Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-γ activation. Diabetes 50:411-417
19. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andressen M, Larsen TS 2002 Cardiac function and metabolism in type 2 diabetic mice after treatment with BM17.0744, a novel ppar-α activator. Am J Physiol Heart Circ Physiol 283:H949-H957
20. Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye J-M, Sauerberg P, Wassermann K 2003 Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 284: E841-E854
21. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y 2000 Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a camp-dependent pathway. Circulation 102: 1296-1301
22. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L 2001 Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108: 1875-1881
23. Fruebis J, Tsao T-S, Javorschi S 2001 Proteolytic cleavage product of 30 kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010
24. Yamauchi T, Kamon J, Waki H 2001 The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946
25. Hofmann C, Lorenz K, Williams D, Palazuk BJ, Colca JR 1995 Insulin sensitization in diabetic rat liver by an antihyperglycemic agent. Metabolism 44:384-389
26. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA 2001 Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277
27. Day C 1999 Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16:179-192
28. Reginato MJ, Lazar MA 1999 Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 10:9-13
29. Popov KM, Kedishvili NY, Zhao Y, Shimomura Y, Crabb DW, Harris RA 1993 Primary structure of pyruvate dehydrogenase kinase establishes a new family of eukaryotic protein kinases. J Biol Chem 268:26602-26606
30. Popov KM, Kedishvili NY, Zhao Y, Gudi R, Harris RA 1994 Molecular cloning of the p445 subunit of pyruvate dehydrogenase kinase. J Biol Chem 269:29720-29724
31. Rowles J, Scherer SW, Xi T 1996 Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in humans. J Biol Chem 271:22376-22398
32. Lawson JE, Niu XD, Browning KS, Trong HL, Yan J, Reed LJ 1993 Molecular cloning and expression of the catalytic subunit of bovine pyruvate dehydrogenase phosphatase and sequence similarity with protein phosphatase 2C. Biochemistry 32:8987-8993
33. Huang B, Gudi R, Wu P, Harris RA, Hamilton J, Popov KM 1998 Isoenzymes of pyruvate dehydrogenase phosphatase. DNA-derived amino acid sequences, expression, and regulation. J Biol Chem 273:17680-17688
34. Wu P, Peters JM, Harris RA 2001 Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor α. Biochem Biophys Res Comm 287:391-396
35. Agnihotri G, Liu H-W 2003 Enoyl-CoA hydratase: reaction, mechanism, and inhibition. Bioorg Med Chem 11: 9-20
36. Flier JS, Lowell BB 1997 Obesity research springs a protein leak. Nat Genet 15:223-224
37. Ricquier D, Bouillaud, F 1997 The mitochondrial uncoupling protein: structural and genetic studies. Prog Nucleic Acid Res Mol Biol 56:83-108
38. Jacobsson A, Stadler U, Glotzer MA, Kozak LP 1985 Mitochondrial uncoupling protein from mouse brown fat. Molecular cloning and genetic mapping, and mRNA expression. J Biol Chem 260:16250-16254
39. Bouillaud F, Weissenbach J, Ricquier D 1986 Complete cDNA-derived amino acid sequence of rat brown fat uncoupling protein. J Biol Chem 261:1487-1490
40. Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dulloo A, Seydoux J, Muzzin P, Giacobino J-P 1997 Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett 408:39-42
41. Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB 1997 UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun 235:79-82
42. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH 1997 Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 15:269-272
43. Gimeno RE, Dembski M, Weeng X 1997 Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. Diabetes 46:900-906
44. Lowell BB, Susulic VS, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP, Flier JS 1993 Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366:740-742
45. Kopecky J, Clarke G, Enerback S, Spiegelman B, Kozak LP 1995 Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. J Clin Invest 96:2914-2923
46. Enerback S, Jacobsson A, Simpson EM, Guerra C, Yamashita H, Harper M-E, Kozak LP 1997 Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 387:90-94
47. Wu Z, Puigserver P, Andersson U 1999 Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98: 115-124
48. Boden G 2001 Pathogenesis of type 2 diabetes and insulin resistance. Endocrinol Metab Clin North Am 30: 801-815
49. Roden M, Stingl H, Chandramouli V 2000 Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49:701-707
50. Guan H-P, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA 2002 A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122-1126
51. Goldberg I 1996 Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37:693-707
52. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B 1997 Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 17:1756-1764
53. Wajchenberg GL, Biannella-Neto D, Da Silva ME, Santos RF 2002 Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 34: 616-621
54. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denefle P, Staels B, Branellec D 1996 Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97: 2408-2416
55. Wilson GG, Abou-Donia M, Frith L, Patel J, Fiedorek FT 2000 Monotherapy with GI262570, a tyrosine-based non-thiazolidinedione PPARγ agonist significantly reduces triglyceride and increases HDL-C concentrations in patients with type 2 diabetes mellitus. Diabetes 49(Suppl 1):158OR (Abstract)
56. Rubin EM, Ishida BY, Clift SM, Krauss RM 1991 Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA 88: 434-438
57. Kieft KA, Bocan TMA, Krause BR 1991 Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. J Lipid Res 32:859-866